NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) Stock Analysis

Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

RYTM

$102.74

−$2.15 (−2.05%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare RYTM with… →

RYTM Key Statistics

As of Sep 4, 2026
Trading
Open
$103.53
Previous Close
$104.89
Day's Range
101.25–105.71
52-Week Range
74.50–122.20
Volume
466.90K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.97
Valuation
Market Cap
$7.07B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
29.48
EPS (ttm)Profit attributable to each share over the last twelve months.
−3.05
Financials (FY)
Revenue (FY)
$189.76M+45.83%
Net Income (FY)
−$196.54M
Profit marginThe share of revenue left as profit after all costs and taxes.
−85.59%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
68.85M
1-Year Return
−1.75%
Dividend and dates
Earnings Date
November 3, 2026estimated
Avg Volume
758.87K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

RYTM Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−4.02%
2025+91.21%
2024+21.78%
2023+57.86%
2022+191.78%
2021−66.43%
2020+29.49%
2019−14.58%
2018−7.50%
2017 (partial year)+18.27%

As of September 4, 2026.

RYTM Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$189.76M−$196.54M−103.6%
2024$130.13M−$260.60M−200.3%
2023$77.43M−$184.68M−238.5%
2022$23.64M−$181.12M−766.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$189.76M$170.27M−$192.02M−$196.54M−103.6%
2024$130.13M$116.76M−$265.50M−$260.60M−200.3%
2023$77.43M$68.13M−$184.36M−$184.68M−238.5%
2022$23.64M$21.51M−$179.16M−$181.12M−766.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

RYTM Valuation vs Biotechnology Median

Median of 656 stocks
MetricRYTMBiotechnology medianvs median
P/S ratio29.4815.2693% above
Profit margin−85.59%0.00%85.6 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 16 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) at $7.07B. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 414 employees.

The 52-week range on file runs from $74.50 to $122.20. The most recent close on file for RYTM is $102.74, dated September 4, 2026. That is −$2.15 (−2.05%) against the previous close. The latest close sits 37.91% above that 52-week low.

Financial Health

In fiscal 2025, Rhythm Pharmaceuticals, Inc. Common Stock reported revenue of $189.76M. Against the prior fiscal year total of $130.13M, that is a change of +45.83%. The same year closed with a net loss of $196.54M. Profit margin runs at −85.59%. That is 85.6 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −3.05.

Across the 4 fiscal years on file, revenue moves from $23.64M in 2022 to $189.76M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 29.48 times revenue. On price-to-sales that is 93.17% above the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

The reported beta is 1.97. Annualized volatility over the trailing 8 years is 70.22%. Over the trailing twelve months the price has returned −1.75%. Measured over 5 years, that is +51.32% a year compounded.

Growth & Income

The record shows no dividend for RYTM.

Across the complete calendar years on file, 2022 returned +191.78% and 2021 returned −66.43%. Of the 8 complete calendar years on file, 5 finished higher. 2026 is still running; the price is −4.02% year to date.

Peer Comparison

Rhythm Pharmaceuticals, Inc. Common Stock (RYTM) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Rhythm Pharmaceuticals, Inc. Common Stock RYTM $7.07B —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Rhythm Pharmaceuticals, Inc. Common Stock has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Rhythm Pharmaceuticals, Inc. Common Stock

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic obesity, congenital hypothalamic obesity, pro-opiomelanocortin (POMC) and LEPR insufficiency obesities, SRC1 deficiency obesity, and SH2B1 deficiency obesity; and in phase 2 clinical trails for the treatment of Prader-Willi syndrome and MC4R deficiency. The company is also developing bivamelagon, an investigational oral small molecule MC4R agonist that is in phase 2 clinical trial for the treatment of MC4R pathway diseases; and RM-718, a next generation MC4R peptide agonist that is in phase 1 clinical trial for the treatment of hypothalamic obesity. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.

Visit website →